Tag Archives: Treatment Action Group

Pipeline Report: Speed development of, access to products that will address global health needs

By on .

Imagine a world in which a single once-daily pill that can be taken without food, has few if any side effects, and can control the virus that leads to AIDS, is available, equally, to everyone who needs it. Imagine if governments and health systems all over the world were ready to make use of new […]

CDC report on U.S. TB drug shortage reflects local and global challenges

By on .

With no medicine on hand, a father and his infant who have just been diagnosed with multidrug-resistant tuberculosis go untreated, the delay prolonging their recoveries as well as the time they will remain infectious. The delay adds to the risk that they will get sicker and resistant to more drugs, increases the odds that those […]

FDA panel finds new type of TB drug effective, raising hopes for treatment of drug-resistant strains

By on .

Dr. Dalene von Delft had a choice between dying  or going deaf, and that was a choice only if the arduous treatment she was undergoing for drug-resistant tuberculosis worked. The South African pediatrician had contracted a resistant strain of the disease caring for patients, and the only potentially effective treatment was showing one of its […]

Global Fund TB allocation shows need for work, action, groups say

By on .

When the Global Fund Board released its September meeting “decision points” document on funding allocation methods, it was, watchers noted, a part of a piece of a work in progress. But one decision will hold for the next year, and will impact efforts to roll out advances in tuberculosis diagnosis and treatment — the decision […]

Drug maker seeks approval for use against multidrug-resistant tuberculosis

By on .

Makers of an investigational tuberculosis drug that has been urged for “compassionate use” approval in South Africa have applied to the European Medicines Agency to market the medicine as part of a combination therapy for multidrug-resistant tuberculosis. “If approved, bedaquiline could be one of the first drugs with a new mechanism of action for tuberculosis […]

Mark Harrington: US Cannot Pull Back on HIV Treatment Scale Up

By on .

In this video, Mark Harrington, executive director of the Treatment Action Group, discusses the resources needed to “catch up” with the HIV epidemic and the urgency of expanding treatment to save lives. Harrington explains this pressing need in the context of a shift in US global health policy and the global economic recession. Harrington spoke […]

NIH Funding is "Money Well Spent"

By on .

A new issue brief from The Foundation for AIDS Research and the Treatment Action Group makes a compelling case for increased US investment in NIH research. The issue brief, “A Sound Investment: The Multiplier Effect of AIDS Reserach,” details the broad benefits of AIDS research–not just in advancing HIV treatment but also providing new tools for […]

Two New TB Reports from TAG

By on .

The Treatment Action Group has released two new reports on tuberculosis, both valuable resources in the effort to combat this global TB epidemic. The first report details the level of global funding for TB research and development; a total of $510 million was invested by 71 organizations, public and private, in TB R&D in 2008, […]

TAG Reports Show Paucity of HIV & TB Research Funding

By on .

Two new reports from the Treatment Action Group highlight the underfunding of scientific research on tuberculosis and related diseases.  The first report is aptly called “Flat-Lined,” and it shows that funding for the National Institutes of Health from 2004 to 2009 has not kept up with inflation, translating into a net dip in research investment […]